Inactive Instrument

Analyst Reco. HUTCHISON CHINA MED. London S.E.

Equities

Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20	Nov. 24	MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating	Nov. 10	MT
Hutchmed Says Platelet Disorder Drug Increased Durable Response Rate in Phase 3 Trial	23-08-21	MT
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating	22-08-09	MT
AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate	22-08-08	MT
AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial	22-08-08	MT
Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Shows Improved Response Rates	22-07-13	MT
Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $37	22-05-05	MT
HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy	21-09-22	MT
HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price Target	21-08-03	MT

No results for this search